Just a teaser:

http://www.ncbi.nlm.nih.gov/pubmed/18751...$=pmtitlesearch4

;-)))

Anticancer Res. 2008 Jul-Aug;28(4B):2027-31.

Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Siemann DW, Shi W.

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA. siemadw@ufl.edu

BACKGROUND: This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents. MATERIALS AND METHODS: Human clear cell renal carcinoma (Caki-1) tumors were established in @#$% mice. Treatments consisted of Avastin (2 mg/kg) administered twice a week; CA4P (100 mg/kg) or OXi4503 (25 mg/kg) administered 3 times a week for a period of 2 weeks; or a combination of Avastin and CA4P or OXi4503. Tumor response was assessed by growth delay. RESULTS: The tumor growth delays were 8, 6, and 18 days for Avastin, CA4P, and OXi4503, respectively. When the two therapies were combined, there was a significantly greater tumor response than what was achieved with single-agent treatments. For example, Avastin plus CA4P led to a growth delay of 13 days, and 27 days for Avastin plus OXi4503. CONCLUSION: Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects.

PMID: 18751370 [PubMed - indexed for MEDLINE]